Literature DB >> 27142770

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer.

Shinichi Komiyama1, Hidetaka Katabuchi2, Mikio Mikami3, Satoru Nagase4, Aikou Okamoto5, Kiyoshi Ito6, Kenichiro Morishige7, Nao Suzuki8, Masanori Kaneuchi9, Nobuo Yaegashi10, Yasuhiro Udagawa11, Hiroyuki Yoshikawa12.   

Abstract

The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows-(1) the format has been changed from reviews to clinical questions (CQ), and the guidelines for optimal clinical practice in Japan are now shown as 41 CQs and answers; (2) the 'flow charts' have been improved and placed near the beginning of the guidelines; (3) the 'basic points', including tumor staging, histological classification, surgical procedures, chemotherapy, and palliative care, are described before the chapter; (4) the FIGO surgical staging of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was revised in 2014 and the guideline has been revised accordingly to take the updated version of this classification into account; (5) the procedures for examination and management of hereditary breast and ovarian cancer are described; (6) information on molecular targeting therapy has been added; (7) guidelines for the treatment of recurrent cancer based on tumor markers alone are described, as well as guidelines for providing hormone replacement therapy after treatment.

Entities:  

Keywords:  Fallopian tube cancer; Guideline; Japan Society of Gynecologic Oncology; Ovarian cancer; Primary peritoneal cancer

Mesh:

Year:  2016        PMID: 27142770     DOI: 10.1007/s10147-016-0985-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  4 in total

1.  [Guidelines for proper use of antineoplastic agents. Gynecologic cancer].

Authors:  Kazunori Ochiai; Aiko Okamoto; Noriyuki Katsumata
Journal:  Gan To Kagaku Ryoho       Date:  2002-06

2.  [Guideline for correct use of antineoplastic agents (draft). General theory].

Authors:  Hiroshi Ariyoshi
Journal:  Gan To Kagaku Ryoho       Date:  2002-06

3.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

4.  Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Authors:  Hideki Takeuchi; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura; Kenjiro Aogi; Kenji Eguchi; Kenji Okita; Yoshikazu Kagami; Ryuhei Tanaka; Kazuhiko Nakagawa; Hirofumi Fujii; Narikazu Boku; Makoto Wada; Tatsuo Akechi; Yasuhiro Udagawa; Yutaka Okawa; Yusuke Onozawa; Hidenori Sasaki; Yasuo Shima; Naohito Shimoyama; Masayuki Takeda; Toshihiko Nishidate; Akifumi Yamamoto; Tadashi Ikeda; Koichi Hirata
Journal:  Int J Clin Oncol       Date:  2015-06-17       Impact factor: 3.402

  4 in total
  17 in total

1.  Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.

Authors:  Koji Matsuo; Yongmei Huang; Oliver Zivanovic; Muneaki Shimada; Hiroko Machida; Brendan H Grubbs; Lynda D Roman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2019-07-04       Impact factor: 5.482

2.  miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6.

Authors:  Yunyun Zheng; Kang Zhu; Guihu Wang
Journal:  Clin Exp Metastasis       Date:  2022-04-21       Impact factor: 4.510

Review 3.  The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Authors:  Hideki Tokunaga; Mikio Mikami; Satoru Nagase; Yoichi Kobayashi; Tsutomu Tabata; Masanori Kaneuchi; Toyomi Satoh; Yasuyuki Hirashima; Noriomi Matsumura; Yoshihito Yokoyama; Kei Kawana; Satoru Kyo; Daisuke Aoki; Hidetaka Katabuchi
Journal:  J Gynecol Oncol       Date:  2021-03       Impact factor: 4.401

4.  Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.

Authors:  Kayoko Waki; Kouichiro Kawano; Naotake Tsuda; Kimio Ushijima; Kyogo Itoh; Akira Yamada
Journal:  J Immunol Res       Date:  2017-04-27       Impact factor: 4.818

5.  Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer.

Authors:  Mikio Mikami; Masako Shida; Takeo Shibata; Hidetaka Katabuchi; Junzo Kigawa; Daisuke Aoki; Nobuo Yaegashi
Journal:  J Gynecol Oncol       Date:  2017-12-27       Impact factor: 4.401

6.  Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.

Authors:  Hong Liao; Hongmei Zhu; Shanling Liu; He Wang
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

7.  Asian Society of Gynecologic Oncology International Workshop 2018.

Authors:  Tae Wook Kong; Hee Sug Ryu; Seung Cheol Kim; Takayuki Enomoto; Jin Li; Kenneth H Kim; Seung Hyuk Shim; Peng Hui Wang; Suwanit Therasakvichya; Yusuke Kobayashi; Maria Lee; Tingyan Shi; Shin Wha Lee; Mikio Mikami; Satoru Nagase; Myong Cheol Lim; Jianliu Wang; Sarikapan Wilailak; Sang Wun Kim; Sook Hee Hong; David Sp Tan; Masaki Mandai; Suk Joon Chang; Ruby Yun Ju Huang; Kimio Ushijima; Jung Yun Lee; Xiaojun Chen; Kazunori Ochiai; Taek Sang Lee; Bingyi Yang; Farhana Kalam; Qiaoying Lv; Mohd Faizal Ahmad; Muhammad Rizki Yaznil; Kanika Batra Modi; Manatsawee Manopunya; Dae Hoon Jeong; Arb Aroon Lertkhachonsuk; Hyun Hoon Chung; Hidemichi Watari; Seob Jeon
Journal:  J Gynecol Oncol       Date:  2019-01-14       Impact factor: 4.401

8.  Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis.

Authors:  Masato Yoshihara; Hiroaki Kajiyama; Satoshi Tamauchi; Shiro Suzuki; Kunihiko Takahashi; Shigeyuki Matsui; Fumitaka Kikkawa
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

9.  Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens.

Authors:  Naohisa Yoshida; Tetsuya Taguchi; Masayoshi Nakanishi; Ken Inoue; Tetsuya Okayama; Takeshi Ishikawa; Eigo Otsuji; Koichi Takayama; Haruo Kuroboshi; Motohiro Kanazawa; Yoshito Itoh
Journal:  BMC Pharmacol Toxicol       Date:  2019-01-14       Impact factor: 2.483

10.  Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.

Authors:  Masato Yoshihara; Hiroaki Kajiyama; Akira Yokoi; Mai Sugiyama; Yoshihiro Koya; Yoshihiko Yamakita; Wenting Liu; Kae Nakamura; Yoshinori Moriyama; Hiroaki Yasui; Shiro Suzuki; Yusuke Yamamoto; Carmela Ricciardelli; Akihiro Nawa; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Int J Cancer       Date:  2020-01-24       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.